Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error

DSpace/Manakin Repository

Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error

Citable link to this page

 

 
Title: Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error
Author: Shipitsin, M; Small, C; Choudhury, S; Giladi, E; Friedlander, S; Nardone, J; Hussain, S; Hurley, A D; Ernst, C; Huang, Y E; Chang, H; Nifong, T P; Rimm, D L; Dunyak, J; Loda, M; Berman, D M; Blume-Jensen, P

Note: Order does not necessarily reflect citation order of authors.

Citation: Shipitsin, M., C. Small, S. Choudhury, E. Giladi, S. Friedlander, J. Nardone, S. Hussain, et al. 2014. “Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error.” British Journal of Cancer 111 (6): 1201-1212. doi:10.1038/bjc.2014.396. http://dx.doi.org/10.1038/bjc.2014.396.
Full Text & Related Files:
Abstract: Background: Key challenges of biopsy-based determination of prostate cancer aggressiveness include tumour heterogeneity, biopsy-sampling error, and variations in biopsy interpretation. The resulting uncertainty in risk assessment leads to significant overtreatment, with associated costs and morbidity. We developed a performance-based strategy to identify protein biomarkers predictive of prostate cancer aggressiveness and lethality regardless of biopsy-sampling variation. Methods: Prostatectomy samples from a large patient cohort with long follow-up were blindly assessed by expert pathologists who identified the tissue regions with the highest and lowest Gleason grade from each patient. To simulate biopsy-sampling error, a core from a high- and a low-Gleason area from each patient sample was used to generate a ‘high' and a ‘low' tumour microarray, respectively. Results: Using a quantitative proteomics approach, we identified from 160 candidates 12 biomarkers that predicted prostate cancer aggressiveness (surgical Gleason and TNM stage) and lethal outcome robustly in both high- and low-Gleason areas. Conversely, a previously reported lethal outcome-predictive marker signature for prostatectomy tissue was unable to perform under circumstances of maximal sampling error. Conclusions: Our results have important implications for cancer biomarker discovery in general and development of a sampling error-resistant clinical biopsy test for prediction of prostate cancer aggressiveness.
Published Version: doi:10.1038/bjc.2014.396
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453845/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:17295784
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters